Does the media favor ORGO or PAHC?

In the previous week, Phibro Animal Health had 4 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for Phibro Animal Health and 3 mentions for Organogenesis. Phibro Animal Health's average media sentiment score of 0.69 beat Organogenesis' score of 0.67 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AVBP or ORGO?

In the previous week, ArriVent BioPharma had 2 more articles in the media than Organogenesis. MarketBeat recorded 5 mentions for ArriVent BioPharma and 3 mentions for Organogenesis. ArriVent BioPharma's average media sentiment score of 1.26 beat Organogenesis' score of 0.67 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AKTS or ORGO?

In the previous week, Aktis Oncology had 1 more articles in the media than Organogenesis. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.67 beat Aktis Oncology's score of 0.54 indicating that Organogenesis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AVLN or ORGO?

In the previous week, Organogenesis had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Avalyn Pharma. Organogenesis' average media sentiment score of 0.67 beat Avalyn Pharma's score of 0.04 indicating that Organogenesis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ORGO or ARDX?

Organogenesis has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organogenesis $512.59M 0.60 $37.03M -$0.19 N/A Ardelyx $407.32M 3.00 -$61.60M -$0.23 N/A

Is ORGO or ARDX more profitable?

Organogenesis has a net margin of -0.84% compared to Ardelyx's net margin of -13.58%. Organogenesis' return on equity of 9.63% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Organogenesis -0.84% 9.63% 4.76% Ardelyx -13.58% -38.11% -11.85%

Does the media prefer ORGO or ARDX?

In the previous week, Ardelyx had 4 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for Ardelyx and 3 mentions for Organogenesis. Ardelyx's average media sentiment score of 0.74 beat Organogenesis' score of 0.67 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Organogenesis (ORGO) Competitors

$2.40 +0.03 (+1.05%)

As of 12:50 PM Eastern

Compare

ORGO vs. PAHC, AVBP, AKTS, AVLN, and ARDX

Should you buy Organogenesis stock or one of its competitors? MarketBeat compares Organogenesis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organogenesis include Phibro Animal Health (PAHC), ArriVent BioPharma (AVBP), Aktis Oncology (AKTS), Avalyn Pharma (AVLN), and Ardelyx (ARDX).

How does Organogenesis compare to Phibro Animal Health?

Organogenesis (NASDAQ:ORGO) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Phibro Animal Health had 4 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for Phibro Animal Health and 3 mentions for Organogenesis. Phibro Animal Health's average media sentiment score of 0.69 beat Organogenesis' score of 0.67 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health has higher revenue and earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$512.59M	0.60	$37.03M	-$0.19	N/A
Phibro Animal Health	$1.30B	1.14	$48.26M	$2.33	15.65

Organogenesis has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 18.8% of Organogenesis shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Phibro Animal Health has a net margin of 6.35% compared to Organogenesis' net margin of -0.84%. Phibro Animal Health's return on equity of 37.14% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Phibro Animal Health	6.35%	37.14%	8.57%

Organogenesis currently has a consensus price target of $5.75, suggesting a potential upside of 140.08%. Phibro Animal Health has a consensus price target of $42.50, suggesting a potential upside of 16.55%. Given Organogenesis' higher probable upside, equities research analysts plainly believe Organogenesis is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Phibro Animal Health beats Organogenesis on 12 of the 14 factors compared between the two stocks.

How does Organogenesis compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Organogenesis has higher revenue and earnings than ArriVent BioPharma. Organogenesis is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Organogenesis	$512.59M	0.60	$37.03M	-$0.19	N/A

ArriVent BioPharma presently has a consensus target price of $44.83, indicating a potential upside of 52.29%. Organogenesis has a consensus target price of $5.75, indicating a potential upside of 140.08%. Given Organogenesis' higher probable upside, analysts plainly believe Organogenesis is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ArriVent BioPharma has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Organogenesis	-0.84%	9.63%	4.76%

In the previous week, ArriVent BioPharma had 2 more articles in the media than Organogenesis. MarketBeat recorded 5 mentions for ArriVent BioPharma and 3 mentions for Organogenesis. ArriVent BioPharma's average media sentiment score of 1.26 beat Organogenesis' score of 0.67 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 18.8% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ArriVent BioPharma has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

Summary

ArriVent BioPharma and Organogenesis tied by winning 8 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

In the previous week, Aktis Oncology had 1 more articles in the media than Organogenesis. MarketBeat recorded 4 mentions for Aktis Oncology and 3 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.67 beat Aktis Oncology's score of 0.54 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aktis Oncology currently has a consensus price target of $34.60, indicating a potential upside of 59.82%. Organogenesis has a consensus price target of $5.75, indicating a potential upside of 140.08%. Given Organogenesis' higher probable upside, analysts clearly believe Organogenesis is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Organogenesis has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$8.28M	139.69	-$63.73M	-$0.38	N/A
Organogenesis	$512.59M	0.60	$37.03M	-$0.19	N/A

Aktis Oncology has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Aktis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Organogenesis	-0.84%	9.63%	4.76%

Summary

Organogenesis beats Aktis Oncology on 10 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

Organogenesis has higher revenue and earnings than Avalyn Pharma. Organogenesis is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$21.83	N/A
Organogenesis	$512.59M	0.60	$37.03M	-$0.19	N/A

Avalyn Pharma has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Avalyn Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Organogenesis	-0.84%	9.63%	4.76%

In the previous week, Organogenesis had 1 more articles in the media than Avalyn Pharma. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Avalyn Pharma. Organogenesis' average media sentiment score of 0.67 beat Avalyn Pharma's score of 0.04 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalyn Pharma presently has a consensus price target of $59.00, suggesting a potential upside of 108.48%. Organogenesis has a consensus price target of $5.75, suggesting a potential upside of 140.08%. Given Organogenesis' higher possible upside, analysts plainly believe Organogenesis is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

49.6% of Organogenesis shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Organogenesis beats Avalyn Pharma on 9 of the 14 factors compared between the two stocks.

How does Organogenesis compare to Ardelyx?

Organogenesis (NASDAQ:ORGO) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Organogenesis currently has a consensus price target of $5.75, suggesting a potential upside of 140.08%. Ardelyx has a consensus price target of $15.73, suggesting a potential upside of 218.04%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Ardelyx had 4 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for Ardelyx and 3 mentions for Organogenesis. Ardelyx's average media sentiment score of 0.74 beat Organogenesis' score of 0.67 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organogenesis has a net margin of -0.84% compared to Ardelyx's net margin of -13.58%. Organogenesis' return on equity of 9.63% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Ardelyx	-13.58%	-38.11%	-11.85%

Organogenesis has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$512.59M	0.60	$37.03M	-$0.19	N/A
Ardelyx	$407.32M	3.00	-$61.60M	-$0.23	N/A

Organogenesis has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Summary

Organogenesis beats Ardelyx on 9 of the 17 factors compared between the two stocks.

Get Organogenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGO vs. The Competition

Export

Metric	Organogenesis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$308.18M	$3.52B	$6.80B	$12.66B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-12.61	7.38	282.16	25.05
Price / Sales	0.60	1,220.59	576.18	79.91
Price / Cash	3.66	44.80	28.60	46.71
Price / Book	1.01	16.79	10.96	6.18
Net Income	$37.03M	-$12.56M	$3.49B	$347.61M
7 Day Performance	-6.08%	-0.84%	0.45%	0.71%
1 Month Performance	1.48%	-7.59%	-4.26%	-3.75%
1 Year Performance	-46.90%	49.20%	63.09%	20.17%

Organogenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGO Organogenesis	1.6617 of 5 stars	$2.40 +1.1%	$5.75 +140.1%	-47.5%	$308.18M	$512.59M	N/A	950	Upcoming Earnings
PAHC Phibro Animal Health	4.6682 of 5 stars	$32.98 -1.0%	$42.50 +28.9%	+39.1%	$1.34B	$1.50B	14.13	2,475	Dividend Announcement
AVBP ArriVent BioPharma	2.5644 of 5 stars	$27.90 -1.1%	$44.83 +60.7%	+59.8%	$1.30B	N/A	N/A	40	News Coverage Upcoming Earnings
AKTS Aktis Oncology	2.2642 of 5 stars	$24.31 +1.5%	$34.60 +42.3%	N/A	$1.29B	$6.50M	N/A	76	Upcoming Earnings
AVLN Avalyn Pharma	3.0566 of 5 stars	$28.59 -0.1%	$59.00 +106.4%	N/A	$1.27B	N/A	N/A	51

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGO) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organogenesis (ORGO) Competitors

ORGO vs. PAHC, AVBP, AKTS, AVLN, and ARDX

How does Organogenesis compare to Phibro Animal Health?

Summary

How does Organogenesis compare to ArriVent BioPharma?

Summary

How does Organogenesis compare to Aktis Oncology?

Summary

How does Organogenesis compare to Avalyn Pharma?

Summary

How does Organogenesis compare to Ardelyx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organogenesis (ORGO) Competitors

ORGO vs. PAHC, AVBP, AKTS, AVLN, and ARDX

How does Organogenesis compare to Phibro Animal Health?

Does the media favor ORGO or PAHC?

Which has stronger earnings and valuation, ORGO or PAHC?

Which has more volatility & risk, ORGO or PAHC?

Do insiders and institutionals hold more shares of ORGO or PAHC?

Is ORGO or PAHC more profitable?

Do analysts recommend ORGO or PAHC?

Summary

How does Organogenesis compare to ArriVent BioPharma?

Which has higher earnings and valuation, AVBP or ORGO?

Do analysts recommend AVBP or ORGO?

Is AVBP or ORGO more profitable?

Does the media refer more to AVBP or ORGO?

Do insiders & institutionals have more ownership in AVBP or ORGO?

Which has more volatility and risk, AVBP or ORGO?

Summary

How does Organogenesis compare to Aktis Oncology?

Does the media favor AKTS or ORGO?

Do analysts recommend AKTS or ORGO?

Do insiders and institutionals have more ownership in AKTS or ORGO?

Which has preferable valuation and earnings, AKTS or ORGO?

Is AKTS or ORGO more profitable?

Summary

How does Organogenesis compare to Avalyn Pharma?

Which has stronger earnings & valuation, AVLN or ORGO?

Is AVLN or ORGO more profitable?

Does the media favor AVLN or ORGO?

Do analysts prefer AVLN or ORGO?

Do insiders & institutionals have more ownership in AVLN or ORGO?

Summary

How does Organogenesis compare to Ardelyx?

Do institutionals & insiders hold more shares of ORGO or ARDX?

Do analysts rate ORGO or ARDX?

Does the media prefer ORGO or ARDX?

Is ORGO or ARDX more profitable?

Which has preferable valuation & earnings, ORGO or ARDX?

Which has more risk and volatility, ORGO or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools